For the pharmaceutical industry supplying products to the United States, 20 August 1997 was the start of a new era. This was the day that the U.S. Food and Drug Administration (FDA) finally introduced its regulation entitled “Electronic Records; Electronic Signatures” [1]. This opened the door unequivocally to the use of electronic recording and signature technologies in the regulated pharmaceutical environment.